Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $11.01 million.

2024 Financial Guidance

Operating Expenses (excluding share-based compensation): The Company expects full year 2024 R&D expense of $30 million to $36 million and SG&A expense of $45 million to $55 million, in each case excluding share-based compensation.

Share-Based Compensation: The Company expects full year share-based compensation expense of $18 million to $22 million.

Non-GAAP Profit / Loss From Continuing Operations: The Company expects Non-GAAP Loss in the first half of 2024 and approach non-GAAP breakeven in the second half of 2024; limited cash burn expected in 2024.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.